Comparison of Stereotactic Body Radiation Therapy Combined With or Without Transcatheter Arterial Chemoembolization for Patients With Small Hepatocellular Carcinoma Ineligible for Resection or Ablation Therapies
Open Access
- 1 January 2018
- journal article
- research article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 17
Abstract
To compare the efficacy and safety of stereotactic body radiation therapy with or without transcatheter arterial chemoembolization for patients with small hepatocellular carcinoma who were ineligible for resection or ablation therapies. A total of 150 patients with 185 hepatocellular carcinoma (≤3 nodules, Child-Turcotte-Pugh class A or B, and no vascular or extrahepatic metastases) were treated with stereotactic body radiation therapy. In principle, transcatheter arterial chemoembolization was combined before stereotactic body radiation therapy (combination group), but some patients were treated with stereotactic body radiation therapy alone. The prescribed dose of stereotactic body radiation therapy was 48 Gy in 4 fractions at the isocenter and 40 Gy in 4 or 5 fractions at the dose covering 95% of the planning target volume. The overall survival, progression-free survival, local progression free survival, and complication rates were retrospectively compared between the groups. Local progression was defined as irradiated tumor growth in dynamic computed tomography follow-up. Tumor responses were assessed according to the Modified Response Evaluation Criteria in Solid Tumors. Treatment-related toxicities were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0. Twenty-eight and 122 patients were enrolled in the stereotactic body radiation therapy alone and combination groups, respectively. The median follow-up periods were 16 and 29 months, respectively. The 2-year overall, progression-free, and local progression-free survival times in stereotactic body radiation therapy alone and combination groups were 78.6% and 80.3% (P = .6583), 49.0% and 42.9% (P = .188), and 71.4% and 80.8% (P = .9661), respectively. The incidence of ≥grade 3 toxicities was 17.9% in stereotactic body radiation therapy alone group and 18.9% in combination group (P = .903). Stereotactic body radiation therapy alone may be a good treatment option for patients with small hepatocellular carcinoma who were ineligible for resection or ablation therapies.Keywords
Funding Information
- Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (17K10478)
This publication has 17 references indexed in Scilit:
- Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2018
- Advances in Stereotactic Body Radiation Therapy for Hepatocellular CarcinomaSeminars in Radiation Oncology, 2017
- Dosimetric impact of Lipiodol in stereotactic body radiation therapy on liver after trans‐arterial chemoembolizationMedical Physics, 2016
- Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cmBMC Cancer, 2016
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular CarcinomaGastroenterology, 2016
- Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular CarcinomaJAMA Oncology, 2015
- Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapiesHepatology Research, 2014
- Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patientsActa Oncologica, 2013
- Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancerBMC Cancer, 2010
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010